»The majority of patients in both risk groups (60% of high-risk and 83% of low-risk) initiated treatment with phlebotomy monotherapy, and during a median follow-up period of 808 days, the vast majority (81% low-risk, 74% high-risk) maintained their original therapy during the follow-up period.
Hematocrit control was suboptimal in both risk groups; 54% of high-risk patients initiating with phlebotomy monotherapy sometimes/always had HCT levels > 50%; among low-risk patients, 64% sometimes/always had HCT levels above 50%.
Overall, 16% of individuals experienced at least 1 TE subsequent to treatment initiation, 20% (n = 3920) among high-risk and 8% (n = 629) among low-risk patients.
This real-world study suggests that currently available PV treatments may not be used to full advantage »
Consistent with what we've been learning, Plb is not the best long term solution. The alternative was HU. Missing are the more recent options of IFN and Rux.
"High-risk patients initiating treatment with phlebotomy monotherapy were associated with the most unfavorable HCT results" and "Among ... low-risk patients retaining phlebotomy monotherapy, HCT results were the least favorable, ..."
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.